AMERICAN JOINT COMMITTEE ON CANCER

美国癌症联合委员会(AJCC)一直在进行一项 制定癌症分期的临床研究项目 在所有的解剖地点中。对AJCC的迫在眉睫的指示源于其 出版《手册》三个版本的过往成就 癌症分期。AJCC的一个新治理是舞台的稳定性。 联合协调委员会计划开展的未来活动包括： 1.通过与其他建议的比较来提炼当前的建议 建立分阶段并在合理情况下调整的制度，以 使之兼容，即儿科肿瘤和妇科部位。 2.确定不同阶段之间的差异和达成的协调 AJCC和国际抗癌联合会(UICC)的系统。 这两个组织未来的出版物将反映这些 和解。 3.继续研究分子标记和预后的重要性 指数及其在分期中的作用。 4.探索鼓励接受和使用互联网的手段和方法 分阶段分类，大力推广价值和使用 研究方案、医学院、住院医师培训中的系统 计划、临床实践、研究、出版物和最终结果 报道。 5.调查在网上发表文章的必要性和可行性 癌症在特定部位或某些生理系统的分期， 即泌尿生殖和妇科，以适应 肿瘤学实践，并鼓励使用分期分类。 6.根据国家和国际标准制定分阶段计划 以下站点的小组：卡波西肉瘤，脊髓，小 肠道，间皮瘤，输卵管，恶性类癌， 肿瘤转移到大脑和肝脏。 7.完善、宣传、分发和鼓励使用网站- 具体的癌症数据收集表格。

The American Joint Committee on Cancer (AJCC) has been engaged in a clinical research project to develop staging classifications for cancers of all anatomic sites. Imminent directives for the AJCC derive from its past accomplishments of publication of three editions of the Manual for Staging Cancer. A new governance for the AJCC is stability in staging. Planned future activities of the AJCC include: 1. Refine present recommendations through comparisons with other established systems for staging and adjustments, where justified, to make compatible, i.e., pediatric tumors and gynecologic sites. 2. Identify variances and reaching accommodations between the staging systems of the AJCC and the International Union Against Cancer (UICC). Future publications of both organizations will reflect these reconciliations. 3. Continue studying the importance of molecular markers and prognostic indices and their role in staging. 4. Explore means and methods to encourage acceptance and use of the staging classifications and vigorously promote the value and use of the system in research protocols, medical schools, residency training programs, clinical practice, research, publications, and end-results reporting. 5. Investigate the need and feasibility of publishing articles on staging of cancer at specific sites or for certain physiologic systems, i.e., genitourinary and gynecologic, to accommodate the specialties of oncology practice and to encourage use of the staging classifications. 6. Develop staging schemes in accordance with national and international groups for the following sites: Kaposi's sarcoma, spinal cord, small intestine, mesotheliomas, fallopian tube, malignant carcinoid tumors, and tumors metastatic to the brain and liver. 7. Refine, publicize, distribute, and encourage the use of site- specific, cancer data collection forms.